These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26428262)

  • 1. The application of human phase 0 microdosing trials: A systematic review and perspectives.
    Svendsen P; El-Galaly TC; Dybkær K; Bøgsted M; Laursen MB; Schmitz A; Jensen P; Johnsen HE
    Leuk Lymphoma; 2016; 57(6):1281-90. PubMed ID: 26428262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New ultrasensitive detection technologies and techniques for use in microdosing studies.
    Lappin G; Wagner CC; Langer O; van de Merbel N
    Bioanalysis; 2009 May; 1(2):357-66. PubMed ID: 21083172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
    Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
    Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials.
    Bae SK; Shon JH
    Arch Pharm Res; 2011 Nov; 34(11):1789-98. PubMed ID: 22139681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microdosing studies in humans: the role of positron emission tomography.
    Bauer M; Wagner CC; Langer O
    Drugs R D; 2008; 9(2):73-81. PubMed ID: 18298126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide.
    Burt T; John CS; Ruckle JL; Vuong LT
    Expert Opin Drug Deliv; 2017 May; 14(5):657-672. PubMed ID: 27564533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microdosing and drug development: past, present and future.
    Lappin G; Noveck R; Burt T
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):817-34. PubMed ID: 23550938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel strategies for microdose studies using non-radiolabeled compounds.
    Maeda K; Sugiyama Y
    Adv Drug Deliv Rev; 2011 Jun; 63(7):532-8. PubMed ID: 21345359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microdosing for early biokinetic studies in humans.
    Stenström K; Sydoff M; Mattsson S
    Radiat Prot Dosimetry; 2010; 139(1-3):348-52. PubMed ID: 20167793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of accelerator MS in pediatric drug evaluation.
    Vuong LT; Blood AB; Vogel JS; Anderson ME; Goldstein B
    Bioanalysis; 2012 Aug; 4(15):1871-82. PubMed ID: 22943618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches using molecular imaging technology -- use of PET in clinical microdose studies.
    Wagner CC; Langer O
    Adv Drug Deliv Rev; 2011 Jun; 63(7):539-46. PubMed ID: 20887762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC; Cross JT
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract]   [Full Text] [Related]  

  • 13. The utility of microdosing over the past 5 years.
    Lappin G; Garner RC
    Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1499-506. PubMed ID: 19040326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microdosing: current and the future.
    Lappin G
    Bioanalysis; 2010 Mar; 2(3):509-17. PubMed ID: 21083258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
    Lappin G; Garner RC
    Nat Rev Drug Discov; 2003 Mar; 2(3):233-40. PubMed ID: 12612650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microdosing: the new pharmacokinetic paradigm?
    Zanni GR; Wick JY
    Consult Pharm; 2006 Oct; 21(10):756-76. PubMed ID: 17243857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.
    Bosgra S; Vlaming ML; Vaes WH
    Clin Pharmacokinet; 2016 Jan; 55(1):1-15. PubMed ID: 26242381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 0, including microdosing approaches: Applying the Three Rs and increasing the efficiency of human drug development.
    Burt T; Vuong LT; Baker E; Young GC; McCartt AD; Bergstrom M; Sugiyama Y; Combes R
    Altern Lab Anim; 2018 Dec; 46(6):335-346. PubMed ID: 30657329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microdosing drugs: a versatile technique to detect and assess drug-drug interactions.
    Foerster KI; Burhenne J
    Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):447-448. PubMed ID: 32336179
    [No Abstract]   [Full Text] [Related]  

  • 20. Microdosing Studies in Children: A US Regulatory Perspective.
    Roth-Cline M; Nelson RM
    Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.